Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.41 |
| ▸ | KRAS | P01116 | 2/20 | 0.41 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15205454 | 0.86 | CHRM4 (0.50) | CHRM4ACACBAKR1C3MCHR1KRAS | |
| SCHEMBL29907097 | 0.82 | PDE10A (0.46) | CHRM4ACACBAKR1C3MCHR1KRAS | |
| SCHEMBL23264054 | 0.82 | PDE10A (0.46) | CHRM4ACACBAKR1C3MCHR1KRAS | |
| SCHEMBL26128961 | 0.80 | PANK3 (0.45) | CHRM4KRASPANK3KDM4EALDH1A1 | |
| SCHEMBL20474710 | 0.79 | ACACB (0.46) | CHRM4ACACBAKR1C3MCHR1KRAS | |
| SCHEMBL20474698 | 0.78 | AKR1C3 (0.49) | CHRM4ACACBAKR1C3PANK3PDE10A | |
| SCHEMBL23210837 | 0.75 | USP30 (0.39) | MCHR1AOC3 | |
| SCHEMBL26129799 | 0.75 | OPRK1 (0.39) | ACACB | |
| SCHEMBL390343 | 0.74 | MCHR1 (0.55) | CHRM4MCHR1PDE10AGRIN2DGRIN3B | |
| SCHEMBL390344 | 0.74 | MCHR1 (0.55) | CHRM4MCHR1PDE10AGRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-10-26 | — | — | US | disclosed |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-03-21 | — | — | US | disclosed |
| EP-4045151-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021076602-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20210106588-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210106588-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | CHRM4 4874/4885ACACB 296/4885AKR1C3 1495/4885 |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | CHRM4 4874/4885ACACB 296/4885AKR1C3 1495/4885 |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | CHRM4 4874/4885ACACB 296/4885AKR1C3 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.